NO951822L - Sammensetninger for regulering av cytokinaktiviteten - Google Patents

Sammensetninger for regulering av cytokinaktiviteten

Info

Publication number
NO951822L
NO951822L NO951822A NO951822A NO951822L NO 951822 L NO951822 L NO 951822L NO 951822 A NO951822 A NO 951822A NO 951822 A NO951822 A NO 951822A NO 951822 L NO951822 L NO 951822L
Authority
NO
Norway
Prior art keywords
compositions
compounds
host
substantially purified
purified form
Prior art date
Application number
NO951822A
Other languages
English (en)
Other versions
NO951822D0 (no
Inventor
Irun Robert Cohen
Ofer Lider
Liora Cahalon
Oded Shoseyov
Raanan Margalit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO951822D0 publication Critical patent/NO951822D0/no
Publication of NO951822L publication Critical patent/NO951822L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cosmetics (AREA)

Abstract

Forbindelser omfattende karboksylerte og/eller sulftlnneholdende ollgosaccharlder l vesentlig renset form, Inkludert sammensetninger Inneholdende disse og fremgangsmåter for anvendelse derav er beskrevet for regulering av cytokinaktiviteten l en vert. Sekresjonen av tumornekrosefaktor alfa (TKF-a) kan bil enten Inhlbert eller hemmet selektivt ved admlnlsrerlng til verten en effektiv mengde av forbindelser eller sammensetninger derav omfattende spesifikke ollgo- saccharlder l vesentlig renset form. Farmasøytiske sammensetninger og anvendelser derav for forhindring og/eller behandling av patologiske prosesser som Involverer Induksjon av aktiv cytoklnsekresjon, så som TNF-a samt Initiering av en ønskelig Immunsystem- relatert respons l verten overfor tilstedeværelse av aktlvatorer, Inkludert patogener, er også beskrevet. Forbindelsene og farmasøytiske sammensetninger Ifølge oppfinnelsen kan bil gitt daglig, ved meget lave effektive doser, vanligvis under 0,1 mg/kg til mennesker, eller l Intervaller for å oppnå opp til omtrent 5-8 dager, fortrinnsvis en gang l uken.
NO951822A 1992-11-10 1995-05-09 Sammensetninger for regulering av cytokinaktiviteten NO951822L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97475092A 1992-11-10 1992-11-10
US9673993A 1993-07-23 1993-07-23
PCT/US1993/010868 WO1994011006A1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity

Publications (2)

Publication Number Publication Date
NO951822D0 NO951822D0 (no) 1995-05-09
NO951822L true NO951822L (no) 1995-06-29

Family

ID=26792027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951822A NO951822L (no) 1992-11-10 1995-05-09 Sammensetninger for regulering av cytokinaktiviteten

Country Status (18)

Country Link
EP (2) EP1095657B1 (no)
JP (1) JPH08506322A (no)
CN (1) CN1093904A (no)
AT (1) ATE201327T1 (no)
AU (2) AU686581B2 (no)
CA (1) CA2149116A1 (no)
DE (2) DE69334102T2 (no)
FI (1) FI952267L (no)
HR (1) HRP931389A2 (no)
HU (1) HUT70945A (no)
IL (1) IL107563A (no)
NO (1) NO951822L (no)
NZ (1) NZ258367A (no)
PL (1) PL309001A1 (no)
SI (1) SI9300586A (no)
TW (1) TW257678B (no)
WO (1) WO1994011006A1 (no)
YU (1) YU71393A (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them
AU2002243630A1 (en) 2001-01-23 2002-08-06 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US7285536B2 (en) 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US20060293275A1 (en) * 2004-03-29 2006-12-28 Toshikazu Nakamura Hgf production accelerator containing heparin-like oligosaccharide
ITMI20091445A1 (it) * 2009-08-07 2011-02-08 Inalco S P A A Socio Unico Derivati semi-sintetici del polisaccaride k5 per la prevenzione ed il trattamento del danno tissutale associato a ischemia e/o riperfusione
AR090026A1 (es) 2011-09-08 2014-10-15 Novozymes Bioag As Metodos y composiciones para tratamiento de semillas
ES2970761T3 (es) 2011-09-14 2024-05-30 Novozymes Bioag As Uso de lipoquitooligosacáridos y/o quitooligosacáridos en combinación con microorganismos solubilizadores de fosfato para potenciar el crecimiento de las plantas
RU2564844C1 (ru) 2011-09-23 2015-10-10 Новозимс Биоаг А/С Хитоолигосахариды и способы их применения для усиления роста растений
CN102824352B (zh) * 2011-10-11 2013-09-04 泸州医学院 一种双糖化合物在制备抗肿瘤药物中的用途
CN109730006B (zh) * 2019-03-19 2022-10-18 西华大学 提高动物黑色素含量的方法
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
BR112022018200A2 (pt) 2020-03-12 2022-11-29 Sydney David Cullis Hill Tratamento para infecção por coronavírus e toxicidade de citocinas associadas
US20230298719A1 (en) * 2020-07-19 2023-09-21 Inderpreet Jalli A System and Method for Developing an Alternative Drug Therapy using Characteristics of an Existing Drug Therapy to Produce a Similar Pathway Behavior

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4818816A (en) * 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
FR2538404B1 (no) * 1982-12-28 1985-08-23 Anic Spa
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
JPH0818993B2 (ja) * 1989-11-28 1996-02-28 キッセイ薬品工業株式会社 プロスタグランジンｉ▲下２▼産生増強剤
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
SK120193A3 (en) * 1991-05-02 1994-07-06 Yeda Res & Dev Pharmaceutical composition for the prevention and/or treatment of pathological processes
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them

Also Published As

Publication number Publication date
DE69330252T2 (de) 2002-02-07
EP1095657B1 (en) 2007-01-10
HRP931389A2 (en) 1995-04-30
AU6478398A (en) 1998-06-25
AU5599394A (en) 1994-06-08
EP0669827A1 (en) 1995-09-06
IL107563A0 (en) 1994-02-27
AU699624B2 (en) 1998-12-10
HUT70945A (en) 1995-11-28
HU9501373D0 (en) 1995-06-28
EP1095657A3 (en) 2004-02-25
IL107563A (en) 2006-12-31
AU686581B2 (en) 1998-02-12
SI9300586A (en) 1994-09-30
NZ258367A (en) 1997-02-24
PL309001A1 (en) 1995-09-18
CA2149116A1 (en) 1994-05-26
DE69334102D1 (de) 2007-02-22
YU71393A (sh) 1997-05-28
FI952267A7 (fi) 1995-07-10
DE69334102T2 (de) 2007-10-18
CN1093904A (zh) 1994-10-26
DE69330252D1 (de) 2001-06-28
EP0669827A4 (en) 1996-08-28
EP1095657A2 (en) 2001-05-02
WO1994011006A1 (en) 1994-05-26
ATE201327T1 (de) 2001-06-15
FI952267A0 (fi) 1995-05-10
EP0669827B1 (en) 2001-05-23
NO951822D0 (no) 1995-05-09
TW257678B (no) 1995-09-21
JPH08506322A (ja) 1996-07-09
FI952267L (fi) 1995-07-10

Similar Documents

Publication Publication Date Title
NO951822L (no) Sammensetninger for regulering av cytokinaktiviteten
EP0765160A4 (no)
AU4529596A (en) Pharmaceutical compositions for prevention and treatment of ulcerative colitis
EP0876143A4 (en) TUMORNROSE FACTOR ALPHA (TNF-ALPHA) INHIBITING MEDICINAL PRODUCTS
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
ZA848369B (en) Pharmaceutical compositions containing bilobalid for the treatment of neuropathies
EP0309602A1 (de) Verwendung katabolischer Enzyme zur Herstellung eines Medikaments zum Bekämpfen der erworbenen Immunschwäche (AIDS) und deren Vorstadien (LAS, ARC)
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
PL311639A1 (en) Stable gamma interferon composition in liquid form
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
DE69927584D1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
WO1990001321A3 (en) Method for treating and preventing loss of bone mass
TW325404B (en) Pharmaceutical composition for the safe administration of fatty acids the invention relates to a pharmaceutical composition for the safe administration of fatty acids which is useful in the treatment of cancer, viral infections and other disorders.
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
SE8403659D0 (sv) Synergistic pharmaceutical composition
AU6707196A (en) Pharmaceutical composition containing inhibitors of interferon- gamma
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
AU8452791A (en) 1-phenyl-3-aryl-2-propyne-1-ones
DK171883A (da) Sammensaetning til behandling af kraeft samt fremgangsmaade til fremstilling af sammensaetningen
AU1621888A (en) Pharmaceutical compositions for the treatment of cerebral psycho-organic syndromes
RU95113594A (ru) Композиции для регулирования активности цитокина
GR3024253T3 (en) High dose vitamin a compositions.